NR 566 Week 4 Exam: Advanced Pharmacology - Care of the
Family | 250 Questions & Answers | 2026/2027 Edition |
Chamberlain University
NR 566 Week 4 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam prep document for NR 566 Week 4 covers advanced pharmacology
principles applied to family care across the lifespan. With 250 verified questions and detailed
rationales, it addresses pharmacokinetics, pharmacodynamics, drug interactions, and evidence-based
prescribing for common family practice conditions. Designed for Chamberlain University's Advanced
Pharmacology course, this resource ensures mastery of content required for the Week 4 exam.
Key Features:
Pharmacokinetics and pharmacodynamics across the lifespan
Drug therapy for cardiovascular, respiratory, and endocrine disorders
Antimicrobial and immunologic agent selection
Pain management and controlled substance prescribing
Herbal and over-the-counter medication considerations
Legal and ethical aspects of prescribing for families
Updates for 2026:
- Updated to reflect 2026-2027 clinical practice guidelines
- Incorporated new FDA approvals and black box warnings
- Revised rationales with current evidence-based literature
- Added questions on COVID-19 therapeutics and vaccine considerations
- Enhanced coverage of pediatric and geriatric dosing adjustments
Abstract:
This examination preparation document for NR 566 Week 4 at Chamberlain University comprises 250 meticulously
verified questions and answers covering advanced pharmacological concepts essential for family care. The content
integrates pharmacokinetic and pharmacodynamic principles with clinical application across diverse patient
populations, including pediatrics, pregnant women, and older adults. Emphasis is placed on evidence-based
prescribing, drug interactions, adverse effects monitoring, and therapeutic decision-making for common acute and
chronic conditions encountered in family practice. Each question is accompanied by a detailed rationale
explaining the correct answer and distractor analysis, facilitating deep understanding rather than rote
memorization. The material aligns with the latest 2026-2027 guidelines from authoritative sources such as the
FDA, CDC, and specialty organizations. This resource is designed to support students in achieving a graded A+
performance by reinforcing critical thinking and clinical reasoning skills required for safe and effective
pharmacotherapy management in the family setting.
Keywords:
Advanced Pharmacology, Family Care, NR 566, Chamberlain University, Exam Prep, Pharmacokinetics,
Prescribing, Drug Therapy
Answer Format:
Each question is presented with four answer options (A, B, C, D), followed by the correct answer and a
comprehensive rationale. The rationale explains why the correct answer is right and why each distractor is
incorrect, referencing pharmacological principles and clinical guidelines. This format promotes active learning and
application of knowledge.
Page 1
,Compliance Checklist:
All answers verified against current 2026-2027 guidelines
Rationales include citations to evidence-based sources
Questions cover all major content areas from NR 566 Week 4
Distractors designed to test common misconceptions
Content aligns with Chamberlain University curriculum objectives
Updated to reflect latest FDA approvals and safety alerts
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion; receptor theory; dose-response
relationships; age-related changes
Cardiovascular Pharmacology 41-80 Antihypertensives, antiarrhythmics, heart 16%
failure medications, lipid-lowering agents,
anticoagulants
Respiratory and Allergy 81-110 Asthma and COPD therapies, 12%
Pharmacology antihistamines, decongestants,
corticosteroids, bronchodilators
Endocrine and Metabolic 111-145 Diabetes medications, thyroid agents, 14%
Pharmacology osteoporosis drugs, contraceptives, hormone
replacement therapy
Infectious Disease 146-180 Antibiotics, antivirals, antifungals, 14%
Pharmacology immunizations, antimicrobial stewardship
Pain Management and CNS 181-210 Opioids, NSAIDs, adjuvant analgesics, 12%
Agents anxiolytics, antidepressants, ADHD
medications
Special Populations and 211-250 Pediatric dosing, geriatric considerations, 16%
Legal/Ethical Issues pregnancy and lactation, controlled
substances, prescribing regulations
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min/1.73 m²) presents with
persistent hyperglycemia despite metformin and lifestyle modifications. Which of the following antidiabetic
agents requires the most cautious dosing adjustment or is contraindicated at this level of renal impairment?
A. Liraglutide
B. Saxagliptin
C. Dapagliflozin
D. Pioglitazone
Correct Answer: B. Saxagliptin
Rationale: Saxagliptin and its active metabolite are primarily renally eliminated; dose reduction is required for
eGFR <45, and it is not recommended for eGFR <30. Liraglutide has no dose adjustment for renal impairment but
caution is advised. Dapagliflozin efficacy decreases and risk of acute kidney injury increases; it is not
recommended for eGFR <45. Pioglitazone is hepatically metabolized and does not require renal dose adjustment.
Why Wrong:
A - Liraglutide does not require dose adjustment for renal impairment, though caution is advised.
C - Dapagliflozin is not recommended for eGFR <45 due to reduced efficacy and potential renal risk.
D - Pioglitazone is hepatically metabolized and safe in renal impairment without dose adjustment.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52; ADA Standards of Medical Care
in Diabetes, 2024.
Q2. A patient with hypertension and metabolic syndrome is prescribed an ACE inhibitor. One month later,
serum creatinine increases by 35% from baseline, and potassium is 5.6 mEq/L. Which of the following
mechanisms best explains these laboratory changes?
A. Inhibition of aldosterone release leading to decreased potassium excretion and reduced glomerular filtration
rate due to efferent arteriolar dilation
B. Direct nephrotoxic effect of the ACE inhibitor causing acute tubular necrosis
C. Increased renin release causing angiotensin II-mediated vasoconstriction and reduced renal blood flow
D. Blockade of bradykinin degradation leading to increased capillary permeability and interstitial edema
Correct Answer: A. Inhibition of aldosterone release leading to decreased potassium excretion and reduced
glomerular filtration rate due to efferent arteriolar dilation
Rationale: ACE inhibitors reduce angiotensin II formation, leading to dilation of efferent arterioles, which
decreases glomerular filtration pressure (especially if renal perfusion is compromised). They also decrease
aldosterone secretion, reducing potassium excretion. This often results in a modest rise in creatinine (up to 30%)
and hyperkalemia. Option B is incorrect because ACE inhibitors are not directly nephrotoxic. Option C is opposite:
renin increases but angiotensin II is blocked. Option D describes bradykinin effects, which cause cough, not
hyperkalemia and creatinine rise.
Why Wrong:
B - ACE inhibitors are not directly nephrotoxic; they can cause functional decline in renal perfusion.
C - Renin release increases, but angiotensin II is blocked, so vasoconstriction does not occur.
D - Bradykinin accumulation causes cough and angioedema, not hyperkalemia or creatinine elevation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38; JNC 8 Guidelines.
Q3. A patient on warfarin for atrial fibrillation requires antibiotics for a urinary tract infection. Which of the
following antibiotics is most likely to significantly potentiate the anticoagulant effect of warfarin through
inhibition of warfarin metabolism?
A. Ciprofloxacin
B. Amoxicillin
C. Nitrofurantoin
D. Cephalexin
Correct Answer: A. Ciprofloxacin
Page 3
, Rationale: Ciprofloxacin is a potent inhibitor of CYP1A2 and CYP3A4, which are involved in warfarin metabolism (primarily
S-warfarin via CYP2C9, but also R-warfarin via CYP1A2). Inhibition leads to increased warfarin levels and INR. Amoxicillin
and cephalexin have minimal CYP inhibition; nitrofurantoin has minimal effect on warfarin metabolism, though any antibiotic
can alter gut flora and vitamin K production, but ciprofloxacin's metabolic interaction is more significant.
Why Wrong:
B - Amoxicillin has minimal CYP inhibition and a weaker interaction with warfarin.
C - Nitrofurantoin does not significantly inhibit warfarin metabolism.
D - Cephalexin has negligible effect on warfarin metabolism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 54; Micromedex Drug Interactions.
Q4. Which of the following best describes the pharmacodynamic rationale for using a combination of a
thiazide diuretic and an ACE inhibitor in the treatment of hypertension?
A. Thiazide-induced hypokalemia is counteracted by the potassium-sparing effect of ACE inhibitors, and both
drugs reduce peripheral vascular resistance via different mechanisms.
B. Thiazide diuretics increase renin release, which is then blocked by ACE inhibitors, preventing reflex
tachycardia and enhancing blood pressure reduction.
C. ACE inhibitors increase sodium excretion, which complements the diuretic effect of thiazides, and both
drugs have synergistic vasodilatory effects.
D. Thiazide diuretics reduce plasma volume, while ACE inhibitors reduce cardiac output, leading to additive
blood pressure lowering.
Correct Answer: B. Thiazide diuretics increase renin release, which is then blocked by ACE inhibitors,
preventing reflex tachycardia and enhancing blood pressure reduction.
Rationale: Thiazide diuretics reduce plasma volume and sodium, activating the renin-angiotensin system
(increased renin). ACE inhibitors block the conversion of angiotensin I to angiotensin II, preventing
vasoconstriction and aldosterone release. This counteracts the reflex increase in angiotensin II, leading to greater
blood pressure reduction and minimizing hypokalemia. Option A is partially correct but ACE inhibitors do not
directly spare potassium; they reduce aldosterone, which decreases potassium excretion. Option C is inaccurate
because ACE inhibitors do not increase sodium excretion directly. Option D is incorrect: ACE inhibitors reduce
peripheral resistance, not cardiac output.
Why Wrong:
A - ACE inhibitors reduce aldosterone, leading to potassium retention, but thiazide-induced hypokalemia is
mitigated, not counteracted by a direct potassium-sparing effect.
C - ACE inhibitors do not directly increase sodium excretion; they reduce aldosterone, which slightly
increases sodium excretion but not synergistically with thiazides.
D - ACE inhibitors reduce peripheral resistance, not cardiac output, and thiazides reduce plasma volume, not
cardiac output directly.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38, 39; JNC 8.
Q5. A patient with a history of opioid use disorder is being started on buprenorphine/naloxone for
maintenance therapy. Which of the following statements accurately describes the pharmacological rationale
for including naloxone in this combination product?
A. Naloxone has high oral bioavailability and precipitates withdrawal if the tablet is crushed and injected,
deterring misuse.
B. Naloxone is included to enhance the analgesic effect of buprenorphine through synergistic action at
mu-opioid receptors.
C. Naloxone is added to reduce the abuse potential by causing unpleasant effects when taken sublingually as
directed.
D. Naloxone prolongs the half-life of buprenorphine by inhibiting its hepatic metabolism.
Page 4
Family | 250 Questions & Answers | 2026/2027 Edition |
Chamberlain University
NR 566 Week 4 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam prep document for NR 566 Week 4 covers advanced pharmacology
principles applied to family care across the lifespan. With 250 verified questions and detailed
rationales, it addresses pharmacokinetics, pharmacodynamics, drug interactions, and evidence-based
prescribing for common family practice conditions. Designed for Chamberlain University's Advanced
Pharmacology course, this resource ensures mastery of content required for the Week 4 exam.
Key Features:
Pharmacokinetics and pharmacodynamics across the lifespan
Drug therapy for cardiovascular, respiratory, and endocrine disorders
Antimicrobial and immunologic agent selection
Pain management and controlled substance prescribing
Herbal and over-the-counter medication considerations
Legal and ethical aspects of prescribing for families
Updates for 2026:
- Updated to reflect 2026-2027 clinical practice guidelines
- Incorporated new FDA approvals and black box warnings
- Revised rationales with current evidence-based literature
- Added questions on COVID-19 therapeutics and vaccine considerations
- Enhanced coverage of pediatric and geriatric dosing adjustments
Abstract:
This examination preparation document for NR 566 Week 4 at Chamberlain University comprises 250 meticulously
verified questions and answers covering advanced pharmacological concepts essential for family care. The content
integrates pharmacokinetic and pharmacodynamic principles with clinical application across diverse patient
populations, including pediatrics, pregnant women, and older adults. Emphasis is placed on evidence-based
prescribing, drug interactions, adverse effects monitoring, and therapeutic decision-making for common acute and
chronic conditions encountered in family practice. Each question is accompanied by a detailed rationale
explaining the correct answer and distractor analysis, facilitating deep understanding rather than rote
memorization. The material aligns with the latest 2026-2027 guidelines from authoritative sources such as the
FDA, CDC, and specialty organizations. This resource is designed to support students in achieving a graded A+
performance by reinforcing critical thinking and clinical reasoning skills required for safe and effective
pharmacotherapy management in the family setting.
Keywords:
Advanced Pharmacology, Family Care, NR 566, Chamberlain University, Exam Prep, Pharmacokinetics,
Prescribing, Drug Therapy
Answer Format:
Each question is presented with four answer options (A, B, C, D), followed by the correct answer and a
comprehensive rationale. The rationale explains why the correct answer is right and why each distractor is
incorrect, referencing pharmacological principles and clinical guidelines. This format promotes active learning and
application of knowledge.
Page 1
,Compliance Checklist:
All answers verified against current 2026-2027 guidelines
Rationales include citations to evidence-based sources
Questions cover all major content areas from NR 566 Week 4
Distractors designed to test common misconceptions
Content aligns with Chamberlain University curriculum objectives
Updated to reflect latest FDA approvals and safety alerts
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion; receptor theory; dose-response
relationships; age-related changes
Cardiovascular Pharmacology 41-80 Antihypertensives, antiarrhythmics, heart 16%
failure medications, lipid-lowering agents,
anticoagulants
Respiratory and Allergy 81-110 Asthma and COPD therapies, 12%
Pharmacology antihistamines, decongestants,
corticosteroids, bronchodilators
Endocrine and Metabolic 111-145 Diabetes medications, thyroid agents, 14%
Pharmacology osteoporosis drugs, contraceptives, hormone
replacement therapy
Infectious Disease 146-180 Antibiotics, antivirals, antifungals, 14%
Pharmacology immunizations, antimicrobial stewardship
Pain Management and CNS 181-210 Opioids, NSAIDs, adjuvant analgesics, 12%
Agents anxiolytics, antidepressants, ADHD
medications
Special Populations and 211-250 Pediatric dosing, geriatric considerations, 16%
Legal/Ethical Issues pregnancy and lactation, controlled
substances, prescribing regulations
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min/1.73 m²) presents with
persistent hyperglycemia despite metformin and lifestyle modifications. Which of the following antidiabetic
agents requires the most cautious dosing adjustment or is contraindicated at this level of renal impairment?
A. Liraglutide
B. Saxagliptin
C. Dapagliflozin
D. Pioglitazone
Correct Answer: B. Saxagliptin
Rationale: Saxagliptin and its active metabolite are primarily renally eliminated; dose reduction is required for
eGFR <45, and it is not recommended for eGFR <30. Liraglutide has no dose adjustment for renal impairment but
caution is advised. Dapagliflozin efficacy decreases and risk of acute kidney injury increases; it is not
recommended for eGFR <45. Pioglitazone is hepatically metabolized and does not require renal dose adjustment.
Why Wrong:
A - Liraglutide does not require dose adjustment for renal impairment, though caution is advised.
C - Dapagliflozin is not recommended for eGFR <45 due to reduced efficacy and potential renal risk.
D - Pioglitazone is hepatically metabolized and safe in renal impairment without dose adjustment.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 52; ADA Standards of Medical Care
in Diabetes, 2024.
Q2. A patient with hypertension and metabolic syndrome is prescribed an ACE inhibitor. One month later,
serum creatinine increases by 35% from baseline, and potassium is 5.6 mEq/L. Which of the following
mechanisms best explains these laboratory changes?
A. Inhibition of aldosterone release leading to decreased potassium excretion and reduced glomerular filtration
rate due to efferent arteriolar dilation
B. Direct nephrotoxic effect of the ACE inhibitor causing acute tubular necrosis
C. Increased renin release causing angiotensin II-mediated vasoconstriction and reduced renal blood flow
D. Blockade of bradykinin degradation leading to increased capillary permeability and interstitial edema
Correct Answer: A. Inhibition of aldosterone release leading to decreased potassium excretion and reduced
glomerular filtration rate due to efferent arteriolar dilation
Rationale: ACE inhibitors reduce angiotensin II formation, leading to dilation of efferent arterioles, which
decreases glomerular filtration pressure (especially if renal perfusion is compromised). They also decrease
aldosterone secretion, reducing potassium excretion. This often results in a modest rise in creatinine (up to 30%)
and hyperkalemia. Option B is incorrect because ACE inhibitors are not directly nephrotoxic. Option C is opposite:
renin increases but angiotensin II is blocked. Option D describes bradykinin effects, which cause cough, not
hyperkalemia and creatinine rise.
Why Wrong:
B - ACE inhibitors are not directly nephrotoxic; they can cause functional decline in renal perfusion.
C - Renin release increases, but angiotensin II is blocked, so vasoconstriction does not occur.
D - Bradykinin accumulation causes cough and angioedema, not hyperkalemia or creatinine elevation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38; JNC 8 Guidelines.
Q3. A patient on warfarin for atrial fibrillation requires antibiotics for a urinary tract infection. Which of the
following antibiotics is most likely to significantly potentiate the anticoagulant effect of warfarin through
inhibition of warfarin metabolism?
A. Ciprofloxacin
B. Amoxicillin
C. Nitrofurantoin
D. Cephalexin
Correct Answer: A. Ciprofloxacin
Page 3
, Rationale: Ciprofloxacin is a potent inhibitor of CYP1A2 and CYP3A4, which are involved in warfarin metabolism (primarily
S-warfarin via CYP2C9, but also R-warfarin via CYP1A2). Inhibition leads to increased warfarin levels and INR. Amoxicillin
and cephalexin have minimal CYP inhibition; nitrofurantoin has minimal effect on warfarin metabolism, though any antibiotic
can alter gut flora and vitamin K production, but ciprofloxacin's metabolic interaction is more significant.
Why Wrong:
B - Amoxicillin has minimal CYP inhibition and a weaker interaction with warfarin.
C - Nitrofurantoin does not significantly inhibit warfarin metabolism.
D - Cephalexin has negligible effect on warfarin metabolism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 54; Micromedex Drug Interactions.
Q4. Which of the following best describes the pharmacodynamic rationale for using a combination of a
thiazide diuretic and an ACE inhibitor in the treatment of hypertension?
A. Thiazide-induced hypokalemia is counteracted by the potassium-sparing effect of ACE inhibitors, and both
drugs reduce peripheral vascular resistance via different mechanisms.
B. Thiazide diuretics increase renin release, which is then blocked by ACE inhibitors, preventing reflex
tachycardia and enhancing blood pressure reduction.
C. ACE inhibitors increase sodium excretion, which complements the diuretic effect of thiazides, and both
drugs have synergistic vasodilatory effects.
D. Thiazide diuretics reduce plasma volume, while ACE inhibitors reduce cardiac output, leading to additive
blood pressure lowering.
Correct Answer: B. Thiazide diuretics increase renin release, which is then blocked by ACE inhibitors,
preventing reflex tachycardia and enhancing blood pressure reduction.
Rationale: Thiazide diuretics reduce plasma volume and sodium, activating the renin-angiotensin system
(increased renin). ACE inhibitors block the conversion of angiotensin I to angiotensin II, preventing
vasoconstriction and aldosterone release. This counteracts the reflex increase in angiotensin II, leading to greater
blood pressure reduction and minimizing hypokalemia. Option A is partially correct but ACE inhibitors do not
directly spare potassium; they reduce aldosterone, which decreases potassium excretion. Option C is inaccurate
because ACE inhibitors do not increase sodium excretion directly. Option D is incorrect: ACE inhibitors reduce
peripheral resistance, not cardiac output.
Why Wrong:
A - ACE inhibitors reduce aldosterone, leading to potassium retention, but thiazide-induced hypokalemia is
mitigated, not counteracted by a direct potassium-sparing effect.
C - ACE inhibitors do not directly increase sodium excretion; they reduce aldosterone, which slightly
increases sodium excretion but not synergistically with thiazides.
D - ACE inhibitors reduce peripheral resistance, not cardiac output, and thiazides reduce plasma volume, not
cardiac output directly.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38, 39; JNC 8.
Q5. A patient with a history of opioid use disorder is being started on buprenorphine/naloxone for
maintenance therapy. Which of the following statements accurately describes the pharmacological rationale
for including naloxone in this combination product?
A. Naloxone has high oral bioavailability and precipitates withdrawal if the tablet is crushed and injected,
deterring misuse.
B. Naloxone is included to enhance the analgesic effect of buprenorphine through synergistic action at
mu-opioid receptors.
C. Naloxone is added to reduce the abuse potential by causing unpleasant effects when taken sublingually as
directed.
D. Naloxone prolongs the half-life of buprenorphine by inhibiting its hepatic metabolism.
Page 4
